Abstract: The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

Abstract: The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

Abstract: The invention provides compositions comprising bacterial strains and the use of such compositions in the treatment of disease.

Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

Abstract: Compositions comprising at least two non-pathogenic microbes are described herein. The non-pathogenic microbes may be from a first species capable of internalizing and/or metabolizing dietary glycans and/or from a second species capable of consuming and metabolizing free sugar monomers. Methods of making and use in treating and/or preventing the overgrowth of pathogenic bacteria in mammals are also described herein.

Abstract: A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.

Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

Abstract: A plant extract can be produced from a plant material, such as a cannabis plant material, via an ambient temperature distillation followed by a cold trap condensation. The cold trap apparatus has at least one sealable chamber under vacuum connected to a condenser for extracting chemical compositions at an unelevated temperature from a plant material. Desirable chemicals can be volatilized under negative pressure at low temperatures utilizing the cold trap system described herein.

Abstract: A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.

Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.

Abstract: A composition containing a synergistic association of lactitol, lactulose and Rhamnus frangula extract for the treatment of constipation is described.

Abstract: The present disclosure encompasses compositions prepared from Boysenberry and apple, as well as compositions prepared from Boysenberry, apple and blackcurrant. Also encompassed are methods of preparing these compositions and methods of using these compositions, in particular, for treating or preventing disorders of the respiratory system, including amongst others: inflammation, asthma, chronic obstructive pulmonary disease, allergic airways inflammation, reactive airway disease, airway fibrosis, and airway remodelling.

Abstract: To provide a material for improvement in a climacteric symptom such as hot flash. An oral hot flash improvement agent comprising chlorogenic acids as an active ingredient. An oral hot flash improvement agent comprising a coffee bean extract which comprises chlorogenic acids and in which a mass ratio of caffeine/chlorogenic acids is 0.015 or less, as an active ingredient.

Abstract: This product is an herbal tea powder used to treat hyperglycemia (high blood glucose) and prediabetes. Relieving the main symptom of high blood glucose of type 2 diabetes. Research have shown that Cortex lycii (main component of the formula) can reduce blood sugar by stimulating pancreas ? cell.

Abstract: The present invention relates to an herbal composition for the treatment of metabolic syndromes in a subject in need thereof, said composition-comprising Phaleria nisidai, optionally along with hypoglycemic agents, a process thereof and also, a method of metabolic syndromes.

Abstract: The present invention relates to cosmetic and pharmaceutical compositions each containing a composite extract. More specifically, the present invention provides cosmetic and pharmaceutical compositions, each of which contains, as an active ingredient, a composite extract of an aloe extract and an upland rice extract, leading to excellent moisturizing, anti-inflammatory, and atopy alleviating effects, and thus can be favorably used for prevention, alleviation, and treatment of a skin disease.

Abstract: In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g.

Abstract: The present invention proposes a new use of dipeptide L-glutamic-L-tryptophan acid (L-Glu-L-Trp) for enhancing tissue oxygenation by suppression (reducing a synthesis) of HIF-1? factor in case of diabetic foot, a medical preparation including an effective amount of the dipeptide L-Glu-L-Trp as an active agent and a pharmaceutically acceptable carrier, and a method of treating a diabetic foot including locally administering the mentioned medical preparation comprising the dipeptide L-Glu-L-Trp in a dose of 1.0 ?g per kg-10.0 ?g per kg of body weight at least once a day for a period necessary to achieve a therapeutic effect. The technical result of invention includes providing a peptide preparation, which exerts an antihypoxic effect in diabetes mellitus of both types.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: Leucine-rich repeat-containing G-protein coupled receptor 5-positive (LGR5+) intestinal cells are contacted with an inhibitor of exportin 1 (XPO1), thereby producing functionally differentiated intestinal cells. The LGR5+ cells can also be contacted with a Wnt agonist. The LGR5+ cells can also be contacted with a Notch inhibitor.

Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

Abstract: A method of treating PTSD combines oxytocin with an additional neurotransmitter and, optionally, a minor amount of an amino acid amastatin. The composition may be deployed as either a lozenge or as a topical cream. Also, an effective legal quantity of CBD oil may be used conjointly therewith, whether directly incorporated in the composition or used separately.

Abstract: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include assessing a baseline serum creatinine level prior to administration of terlipressin to the patient, initiating dosing of about 0.5 mg to about 1 mg of terlipressin to the patient every 6 hours by IV for 1-3 days, assessing a serum creatinine level in the patient at day 4±1 day from initiating dosing, administering a modified dosage of terlipressin based on a comparison of the assessed serum creatinine level at day 4±1 day and the baseline serum creatinine level, and continuing administration until 24 hours after two consecutive serum creatinine levels of ?1.5 mg/dL at least 2 hours apart for a maximum of 14 days. The treatment may result in verified reversal of the HRS-1.

Abstract: A solid antimicrobial hydrogel comprising a first amphiphilic component. The first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the composition further comprising an antimicrobial agent being covalently attached to at least one of the hydrophilic or hydrophobic domains.

Abstract: Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.

Abstract: Compositions that are aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporin A), a pharmaceutically acceptable water soluble solvent for the cyclosporin, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed.

Abstract: Provided are combination therapies for treating and preventing relapse of a tumor and infectious diseases in a subject, as well as methods for use thereof. The combination therapies comprise an Hsp70 based pharmaceutical ingredient and at least one further immunotherapeutic agent that specifically inhibits and/or preferably binds to an immune checkpoint molecule or tumor immune microenvironment immune regulator. Furthermore, a kit and methods of using the combination therapies of the invention are described.

Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract: Methods of treating a malignant solid tumor in a patient in need thereof are provided, the methods including administering to the patient a combination therapy comprising: fractionated radiation therapy and a therapeutically effective amount of saposin C (SapC) and dioleoylphosphatidylserine (SapC-DOPS), wherein the fractionated radiation therapy includes a plurality of radiation fractions, each of said fractions delivering a radiation dose lower than a dose effective to inhibit tumor growth when administered alone. Also provided are methods of enhancing anti-tumor efficacy of SapC-DOPS.

Abstract: In the present invention, inventors study in fibrotic ILD/IPF mechanism, the role of Arp2/3 multiprotein complex which regulates the branched polymerization of the actin cytoskeleton, and may play key roles in mechanotranduction. Inventors demonstrated that the expression of the Arp2/3 complex is increased in IPF lung mesenchymal cells and in mouse lungs during fibrogenesis, and that the inhibition of Arp2/3 complex with the small molecule CK666 blocks collagen expression in the lungs and prevents the development of bleomycin-induced lung fibrosis in mice. Accordingly the present invention relates to an inhibitor of Arp2/3 complex activity or expression for use in a method for treating Fibrotic interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis in a subject in need thereof.

Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

Abstract: A method of inducing cell death in a glioblastoma multiforme cancer cell is provided, the method comprising administering to the cell a combination of therapeutic agents comprising: saposin C and dioleoylphosphatidylserine (SapC-DOPS), and nucleolin aptamer AS1411, wherein cell death of the cancer cell is induced.

Abstract: In one aspect, methods of promoting asymmetric nerve growth and/or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.

Abstract: Disclosed herein are methods for promoting neuronal outgrowth in a subject with a neuronal lesion in their CNS by administering effective amounts of a pro-regenerative OPN fragment, optionally with IGF1 and/or BDNF. A voltage gated potassium channel blocker can also be administered. Pharmaceutical compositions, devices for administration, and kits are also disclosed.

Abstract: The present invention relates to methods of treating subjects suffering from a pulmonary NTM infection refractory to treatment, for example to antibiotic treatment.

Abstract: Methods and kits for mitigating a toxic effect of at least one of vesicants and caustic gases in a subject in need thereof are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the toxic effect of the vesicant or caustic gas.

Abstract: Methods and kits for mitigating liver injury and promoting liver regeneration and engraftment in a subject treated with a targeted radiation therapy are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced liver diseases and promote beneficial effects for liver regeneration and engraftment in conjunction with radiation or radiomimetics.

Abstract: Methods of mitigating vascular injury, promoting organ and hematopoietic recovery, accelerating vascular recovery, and enhancing survival in a subject treated with radiation therapy or chemotherapy are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088, is used at the appropriate times relative to the Total Body Irradiation or Chemotherapy exposure to achieve these prophylactic and/or therapeutic benefits.

Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: Dosing regimens for the administration of complexes comprising IL-15/IL-15Ra in combination with an anti-PD-1 antibody molecule to patients are disclosed. Such dosing regimens can be used for preventing, treating and/or managing disorders such as cancer.

Abstract: Formulations and methods for treating fibromyalgia or chronic pain in humans comprising chronically administering to a human patient experiencing fibromyalgia who is experiencing insulin resistance a pharmaceutical composition comprising a therapeutically effective amount of a drug that treats insulin resistance and a therapeutically effective amount of a drug for treating the pain associated with fibromyalgia. In certain preferred embodiments, the formulation is an oral solid dosage form.

Abstract: The present invention relates to semaglutide for use in weight management.

Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.

Abstract: A composition for use in the treatment of a pseudo aneurysm in a subject, said composition comprising: i) microbubbles; ii) a magnetic material; and iii) a blood clotting agent; said treatment comprising administering said composition directly into the pseudo aneurysm and applying a magnetic field to the pseudo aneurysm so as to retain the blood clotting agent within the pseudo aneurysm for a prolonged time period compared to a case where no magnetic field is applied to the pseudo aneurysm.

Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.

Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and MMF. Also provided are methods of reducing intolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MMF.

Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.